Corcept Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio
Corcept Therapeutics (Menlo Park, CA): 2 reconciled FDA prescription therapies, $409.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Menlo Park, CA |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2038-01-01 |
| 2024 CMS Total Public Spend | $409.6M |
| 2024 Medicare Part D Spend | $341.8M |
| 2024 Medicaid Spend | $67.8M |
| California HCAI SB 17 Filings | 6 WAC filings (max 25.8% 2-yr change) |